Country: United States
Language: English
Source: NLM (National Library of Medicine)
irinotecan hydrochloride (UNII: 042LAQ1IIS) (irinotecan - UNII:7673326042)
Sagent Pharmaceuticals
irinotecan hydrochloride
irinotecan hydrochloride 20 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
- Irinotecan Hydrochloride Injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic carcinoma of the colon or rectum. - Irinotecan Hydrochloride Injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - Irinotecan Hydrochloride Injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. Risk Summary Based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)] . Available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarri
Irinotecan Hydrochloride Injection, USP is available as a sterile, pale yellow, clear, aqueous solution in a vial packaged within a carton in the following packaging configurations: Storage Conditions Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature.] Protect from light and freezing. Retain in carton until time of use. Discard unused portion. Inspect the vial for damage and visible signs of leaks before removing from the carton. If damaged, incinerate the unopened package. Irinotecan Hydrochloride Injection, USP is a hazardous drug. Follow special handling and disposal procedures.1 Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.
Abbreviated New Drug Application
IRINOTECAN HYDROCHLORIDE- IRINOTECAN HYDROCHLORIDE INJECTION, SOLUTION SAGENT PHARMACEUTICALS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE IRINOTECAN HYDROCHLORIDE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR IRINOTECAN HYDROCHLORIDE INJECTION. IRINOTECAN HYDROCHLORIDE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1996 WARNING: DIARRHEA AND MYELOSUPPRESSION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ EARLY AND LATE FORMS OF DIARRHEA CAN OCCUR. EARLY DIARRHEA MAY BE ACCOMPANIED BY CHOLINERGIC SYMPTOMS WHICH MAY BE PREVENTED OR AMELIORATED BY ATROPINE. LATE DIARRHEA CAN BE LIFE THREATENING AND SHOULD BE TREATED PROMPTLY WITH LOPERAMIDE. MONITOR PATIENTS WITH DIARRHEA AND GIVE FLUID AND ELECTROLYTES AS NEEDED. INSTITUTE ANTIBIOTIC THERAPY IF PATIENTS DEVELOP ILEUS, FEVER, OR SEVERE NEUTROPENIA. INTERRUPT IRINOTECAN HYDROCHLORIDE INJECTION AND REDUCE SUBSEQUENT DOSES IF SEVERE DIARRHEA OCCURS. (2.2, 5.1) SEVERE MYELOSUPPRESSION MAY OCCUR. (5.2) RECENT MAJOR CHANGES Dosage and Administration, Dosage in Patients With Reduced UGT1A1 Activity (2.3) 1/2022 Dosage and Administration, Preparation of Infusion Solution (2.5) 1/2022 Dosage and Administration, Safe Handling (2.6) 1/2022 Warnings and Precautions, Increased Risk of Neutropenia in Patients With Reduced UGT1A1 Activity (5.3) 1/2022 INDICATIONS AND USAGE Irinotecan Hydrochloride Injection is a topoisomerase inhibitor indicated for: First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (1) Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. (1) DOSAGE AND ADMINISTRATION Colorectal cancer combination regimen 1: Irinotecan Hydrochloride Injection 125 mg/m intravenous infusion over 90 minutes on days 1, 8, 15, 22 with LV 20 mg/m intravenous bolus infusion on days 1, 8, 15, 22 follo Read the complete document